Acquired von Willebrand disease
ICD-10 D68.04 is a billable code used to indicate a diagnosis of acquired von willebrand disease.
Acquired von Willebrand disease (AvWD) is a bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (vWF), which is crucial for platelet adhesion and aggregation during hemostasis. Unlike hereditary forms of von Willebrand disease, AvWD typically arises secondary to other medical conditions, such as autoimmune disorders, malignancies, or certain medications. Patients may present with symptoms such as easy bruising, prolonged bleeding from cuts, heavy menstrual periods, and spontaneous bleeding episodes. Diagnosis often involves laboratory tests that assess vWF levels and function, platelet counts, and coagulation profiles. Treatment focuses on addressing the underlying condition and may include desmopressin, factor replacement therapy, or antifibrinolytics. Understanding the nuances of AvWD is essential for effective management and coding, as it can significantly impact patient outcomes and healthcare costs.
Detailed lab results, patient history, and treatment plans must be documented.
Patients presenting with unexplained bleeding, bruising, or abnormal lab results.
Ensure accurate documentation of vWF levels and function tests.
Comprehensive assessment of comorbid conditions and medications.
Patients with autoimmune diseases or malignancies presenting with bleeding symptoms.
Document any medications that may contribute to bleeding risk.
Used to assess vWF levels in patients suspected of having AvWD.
Document the reason for testing and any relevant clinical findings.
Hematology specialists should ensure comprehensive lab results are included.
AvWD is often caused by underlying conditions such as autoimmune disorders, malignancies, or the use of certain medications that affect von Willebrand factor levels.
